Paul Altmann

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

Colin Baigent, Martin Landray, Craig Leaper et al. · American Journal of Kidney Diseases · 2005 · 202 citations

Hemodialysis, Heart Failure, Renal Function +9

The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD

Martin Landray, Colin Baigent, Craig Leaper et al. · American Journal of Kidney Diseases · 2006 · 108 citations

Hypertension, Renal Function, Cardiovascular Disease +10

DISTURBANCE OF CEREBRAL FUNCTION BY ALUMINIUM IN HAEMODIALYSIS PATIENTS WITHOUT OVERT ALUMINIUM TOXICITY

Paul Altmann, Chris Hamon, J. Anthony Blair et al. · The Lancet · 1989 · 94 citations

Hemodialysis, Dialysis Therapy, Toxicology +5

Serum Aluminum Levels and Erythrocyte Dihydropteridine Reductase Activity in Patients on Hemodialysis

Paul Altmann, Farah G.H. Al-Salihi, Keith Butter et al. · New England Journal of Medicine · 1987 · 73 citations

Dialysis Therapy, Dhpr Activity, Oxidative Stress +20

ALUMINIUM CHELATION THERAPY IN DIALYSIS PATIENTS: EVIDENCE FOR INHIBITION OF HAEMOGLOBIN SYNTHESIS BY LOW LEVELS OF ALUMINIUM

Paul Altmann, Frank Marsh, David Plowman et al. · The Lancet · 1988 · 61 citations

Hemodialysis, Medicine, Chronic Kidney Disease +3